{
  "docId": "019de075-f154-767b-9f07-479a2da3f64b",
  "docSlug": "d4796e91221d5758021de97ee63957e0",
  "documentTitle": "Exscientia | Investor Presentation Deck | 69 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 33,
  "pageCount": 69,
  "prevPage": 32,
  "nextPage": 34,
  "slideType": "why_now",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "Includes a biological pathway diagram and a honeycomb-style indication map.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-f154-767b-9f07-479a2da3f64b/33",
  "deckHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b",
  "deckJsonHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b.json",
  "deckAnchorHref": "/decks/019de075-f154-767b-9f07-479a2da3f64b#slide-33",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.43,
        "y": 0.83
      },
      "kind": "callout",
      "text": "Potential for first line therapy or for CDK4/6 refractory patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "be480c77-599a-404f-a27d-3fc044a99f2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.04,
        "y": 0.27
      },
      "kind": "chart",
      "text": "Cell Cycle Dysregulation in Cancer",
      "attrs": null,
      "subkind": "pie",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6e1eb69-36ac-4fae-acfd-7c6bf55edea0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.25,
        "x": 0.15,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Biological pathway showing CDK7, CDK4, Pol II, and Rb interactions",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffeaccdd-dd9a-46fb-94f9-7d5e8b4e9ebe",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.07,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "ER+: Oestrogen receptor positive. About 80% of all breast cancers are ER+. Source: Xu et al. 2020 Nature; Sava et al. 2020 Cancer and Metastasis Reviews",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b7a05f6-c0f8-4b02-a1c6-51d3fb08f67c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.3,
        "x": 0.1,
        "y": 0.65
      },
      "kind": "image",
      "text": "CDK7: Potential for multiple cancer indications",
      "attrs": null,
      "subkind": "icon-grid",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "780eb716-599e-40f3-8937-52b799c619db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.43,
        "y": 0.53
      },
      "kind": "list",
      "text": "Transcription and cell cycle dysregulation are both hallmarks of cancer: Inhibiting both may be more effective; Aberrant CDK7 overexpression is common; Majority of cancers are 'transcriptionally addicted'.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c3c5a3f-1887-4931-867d-b41d30ea8002",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.5,
        "x": 0.43,
        "y": 0.26
      },
      "kind": "list",
      "text": "Importance of cell cycle inhibition: CDK4/6 inhibitors have demonstrated potential; Ibrance generated $5.4b sales in 2021; 65-75% of patients show response but acquire resistance.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ad38c85-b05b-4a58-958f-46cab0ddc292",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "Dual targeting of cell cycle and transcription mechanisms",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28cd1638-341d-4d71-9710-3b99119a3e26",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "CDK7: Inhibition provides broad oncology opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03830f05-d2e2-41af-a230-87dd25e0f78b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "Biological Pathway Analysis",
      "slug": null,
      "matchId": "017dd161-23f9-4410-adab-bb0a34ccfc89",
      "evidence": "Diagram of CDK7/CDK4/Pol II interactions",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 69,
      "from": 8,
      "beatId": "96bf0b4a-a49b-4aee-bb3c-8a6ad1f87eda",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The deck presents Exscientia's solution, highlighting its AI-driven platform and its potential to improve clinical trial success rates.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 69,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "89204827-3a6d-41c5-9676-a9c3c4bc7a6d",
      "evidence": "The deck presents Exscientia's approach to precision medicine, highlighting its effectiveness.",
      "position": 1,
      "objective": "Why is Exscientia's approach to precision medicine effective?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}